Compare BCBP & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | CRBP |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.0M | 134.8M |
| IPO Year | 2005 | 2014 |
| Metric | BCBP | CRBP |
|---|---|---|
| Price | $8.31 | $8.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $9.00 | ★ $46.17 |
| AVG Volume (30 Days) | 83.8K | ★ 144.9K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | N/A | ★ 64.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $85.26 | N/A |
| Revenue Next Year | $6.14 | $220.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $7.31 | $4.64 |
| 52 Week High | $10.38 | $20.56 |
| Indicator | BCBP | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 56.49 |
| Support Level | $7.54 | $8.39 |
| Resistance Level | $8.62 | $9.51 |
| Average True Range (ATR) | 0.27 | 0.48 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 55.32 | 82.89 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.